'Potential' New Option for Operable NSCLC

(MedPage Today) -- ORLANDO -- The addition of durvalumab (Imfinzi) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-L1 inhibitor alone could become a new standard option for resectable non-small cell lung cancer (NSCLC)...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news